HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
22 Aug 2017 09:00 AM
RNS
Director's Share Dealing
18 Aug 2017 10:50 AM
RNS
Directors' Share Dealing
15 Aug 2017 10:30 AM
RNS
Directors' Share Dealing
10 Aug 2017 09:35 AM
RNS
Director's Share Dealing
07 Aug 2017 09:45 AM
RNS
Directors' Share Dealing
31 Jul 2017 07:00 AM
RNS
Chi-Med Reports 2017 Interim Results
30 Jun 2017 07:00 AM
RNS
Total Voting Rights
29 Jun 2017 07:00 AM
RNS
Start of Savolitinib Global PRCC Phase III Trial
29 Jun 2017 07:00 AM
RNS
Blocklisting Six Monthly Return
29 Jun 2017 07:00 AM
RNS
Chi-Med to Announce 2017 HY Financial Results
22 Jun 2017 07:00 AM
RNS
Chi-Med starts Ph I/II Trial of HMPL 453 in China
16 Jun 2017 09:57 AM
RNS
Director's Share Dealing
12 Jun 2017 07:00 AM
RNS
Fruquintinib NDA for Advanced CRC Filed with CFDA
06 Jun 2017 07:00 AM
RNS
Phase III Fruquintinib Data presented at ASCO
18 May 2017 07:00 AM
RNS
Chi-Med Presents Clinical Data at ASCO 2017
28 Apr 2017 01:40 PM
RNS
Total Voting Rights
27 Apr 2017 02:10 PM
RNS
Results of Annual General Meeting
07 Apr 2017 07:00 AM
RNS
Pre-clinical Data Presented at AACR
31 Mar 2017 07:00 AM
RNS
Total Voting Rights
29 Mar 2017 08:07 AM
RNS
Vesting of LTIP awards
28 Mar 2017 11:00 AM
RNS
Grant of Share Options under Share Option Scheme
27 Mar 2017 07:00 AM
RNS
2016 Annual Report and Notice of AGM
24 Mar 2017 07:00 AM
RNS
Appointment of Director
21 Mar 2017 10:08 AM
RNS
Chi-Med to host R&D Briefings
20 Mar 2017 08:04 AM
RNS
Directors' Share Dealing
16 Mar 2017 11:25 AM
RNS
Grant of Awards under Long Term Incentive Plan
13 Mar 2017 07:00 AM
RNS
Publication of Form 20-F
13 Mar 2017 07:00 AM
RNS
Final Results
10 Mar 2017 08:11 AM
RNS
Sulfatinib Phase Ib/II Results Presented at ENETS
10 Mar 2017 07:18 AM
RNS
Sulfatinib Phase Ib/II Results Presented at ENETS
03 Mar 2017 07:00 AM
RNS
Positive Fruquintinib Pivotal Phase III Results
28 Feb 2017 10:20 AM
RNS
Change of Directors
20 Feb 2017 07:00 AM
RNS
Start of Phase II Savolitinib PSC trial in China
14 Feb 2017 07:07 AM
RNS
Initiates Phase I of Novel FGFR Inhibitor HMPL-453
14 Feb 2017 07:00 AM
RNS
Savolitinib PRCC Results Presentation at ASCO GU
06 Feb 2017 07:00 AM
RNS
Chi-Med to Announce 2016 Final Results
01 Feb 2017 07:00 AM
RNS
Change of Directors
16 Jan 2017 10:48 AM
RNS
Change of Directors
16 Jan 2017 10:11 AM
RNS
Change of Directors
16 Jan 2017 07:30 AM
RNS
Fruquintinib Phase I/II Clinical Data at ASCO GI
16 Jan 2017 07:29 AM
RNS
Sulfatinib Phase II Study in 2nd Line BTC in China
16 Jan 2017 07:16 AM
RNS
Fruquintinib Combination Study in 1st-Line NSCLC
10 Jan 2017 07:00 AM
RNS
Chi-Med Initiates HMPL-523 Clinical Trials
30 Dec 2016 09:11 AM
RNS
Total Voting Rights
29 Dec 2016 07:40 AM
RNS
Blocklisting Six Monthly Return
20 Dec 2016 07:18 AM
RNS
Director's Share Dealing
14 Dec 2016 07:14 AM
RNS
Director's Share Dealing
06 Dec 2016 07:00 AM
RNS
HMPL-523 Pre-clinical Data Presented at ASH
30 Nov 2016 07:51 AM
RNS
Exercise of Share Options
30 Nov 2016 07:48 AM
RNS
Total Voting Rights

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings